A fully transformed Tate & Lyle is being priced like its old commodity self—CP Kelco integration, synergy capture, and demand normalization could unlock a major re-rating.
Overview
Tate & Lyle has completed a landmark transformation from a commodity-exposed, capital-intensive processor into a high-margin, science-led specialty food and beverage solutions provider. The pivot culminated in June 2024 with the sale of its remaining 49.7% stake in Primient for ~US$350m (£279m), removing exposure to cyclical bulk sweeteners and industrial starch. The “New Tate & Lyle” was then cemented through the $1.8bn acquisition of CP Kelco (Nov 2024), making the group a global leader in “Mouthfeel” (pectin and specialty gums) alongside its Sweetening and Fortification platforms. The enlarged group now operates regionally (Americas/EMEA/APAC) and delivered FY2025 pro forma revenue of £2.124bn with adjusted EBITDA of £446m (21% margin). Near-term, FY2026 faces demand softness—especially in North America—prompting guidance for low-single-digit declines in revenue and EBITDA. Medium-term, management targets 4–6% revenue growth with margin expansion, supported by a $200m productivity program and at least $50m run-rate CP Kelco synergies.